CORONA Remedies Limited Share Price & Analysis
₹1,739▼ -0.22%Updated 8 May 2026, 11:31 am IST
LTP
₹1,739
-0.22%
Open
₹—
High
₹1,760
Low
₹1,718.8
Close
₹1,739
52W High
₹1,744
52W Low
₹1,337
Volume
3K
Lot Size
1
Sector
Healthcare
Market Cap
₹11K Cr
Face Value
₹10
Mid Cap
Price Chart
Fundamentals
P/E
66.2
Sector P/E
39.9
P/B
16.1
EPS
₹24.43
ROE
27.6%
ROCE
31.5%
D/E Ratio
0.1
Div Yield
0%
Book Value
₹108
+
Strengths
- ✓Excellent return on equity (ROE 27.6%)
- ✓Efficient capital deployment (ROCE 31.5%)
- ✓Virtually debt-free
−
Concerns
- ✗Premium to sector peers (P/E 66.2x vs industry 39.9x)
- ✗High premium to book value (P/B 16.1x)
- ✗Trading near 52-week high (₹1,744)
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,841 | ₹4.3L Cr | 35.8 | 5.68 | 16.9 | 20.2 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹6,695 | ₹1.7L Cr | 68.1 | 11.52 | 15.4 | 20.4 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,364 | ₹1.4L Cr | 61.4 | 17.45 | 26.5 | 27 | 0.33 |
| DRREDDY Dr. Reddy's Laboratories Limited | ₹1,297 | ₹1.1L Cr | 19.8 | 3 | 18 | 22.7 | 0.16 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,028 | ₹1.1L Cr | 60.5 | 12.7 | 18.4 | 16.6 | 0.88 |
| CIPLA Cipla Limited | ₹1,354 | ₹1.1L Cr | 22.2 | 3.32 | 17.8 | 22.7 | 0.01 |
| LUPIN Lupin Limited | ₹2,419 | ₹1.1L Cr | 21.2 | 5.63 | 20.6 | 21.3 | 0.32 |
Showing 7 peers in the same sector · Sorted by market cap
Corporate Events
To consider and approve the financial results for the period ended March 31, 2026 and recommend final dividend, if any, on the equity shares of the Company for the financial year ended March 31, 2026.
Dividend10 May 2026
Financials
Quarterly Results
| Metric | Dec 2025 | Sep 2025 | Jun 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|
| Revenue | ₹342 Cr ▼5.3% | ₹361 Cr ▲4.0% | ₹347 Cr ▲16.4% | ₹298 Cr ▼5.1% | ₹314 Cr |
| Op. Profit | ₹83 Cr ▲6.4% | ₹78 Cr ▲11.4% | ₹70 Cr ▲1.4% | ₹69 Cr ▲3.0% | ₹67 Cr |
| OPM | 24.0% ▲9.1% | 22.0% ▲10.0% | 20.0% ▼13.0% | 23.0% ▲9.5% | 21.0% |
| Net Profit | ₹41 Cr ▼21.2% | ₹52 Cr ▲13.0% | ₹46 Cr ▲2.2% | ₹45 Cr ▲4.7% | ₹43 Cr |
| EPS (₹) | 6.75 ▼21.1% | 8.55 ▲13.2% | 7.55 ▲2.7% | 7.35 ▲4.6% | 7.03 |
Values in ₹ Cr · Source: Screener.in
Annual Profit & Loss
| Metric | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|
| Revenue | ₹1.2K Cr ▲17.9% | ₹1.0K Cr ▲14.7% | ₹884 Cr |
| Expenses | ₹956 Cr ▲11.3% | ₹859 Cr ▲13.6% | ₹756 Cr |
| Op. Profit | ₹241 Cr ▲54.5% | ₹156 Cr ▲21.9% | ₹128 Cr |
| OPM | 20.0% ▲33.3% | 15.0% ▲7.1% | 14.0% |
| Other Income | ₹6 Cr ▲20.0% | ₹5 Cr ▼28.6% | ₹7 Cr |
| Interest | ₹11 Cr ▼21.4% | ₹14 Cr ▲250.0% | ₹4 Cr |
| Depreciation | ₹37 Cr ▲32.1% | ₹28 Cr ▲40.0% | ₹20 Cr |
| PBT | ₹199 Cr ▲68.6% | ₹118 Cr ▲6.3% | ₹111 Cr |
| Tax % | 25.0% ▲4.2% | 24.0% ▲4.3% | 23.0% |
| Net Profit | ₹149 Cr ▲65.6% | ₹90 Cr ▲5.9% | ₹85 Cr |
| EPS (₹) | 24.43 ▲65.1% | 14.8 ▲6.6% | 13.89 |
| Div Payout | 30.0% ▲20.0% | 25.0% ▲25.0% | 20.0% |
Values in ₹ Cr · Source: Screener.in
Balance Sheet
| Item | Sep 2025 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Liabilities | ||||
| Equity Capital | ₹61 Cr ▲0.0% | ₹61 Cr ▲0.0% | ₹61 Cr ▲0.0% | ₹61 Cr |
| Reserves | ₹598 Cr ▲9.7% | ₹545 Cr ▲30.1% | ₹419 Cr ▲20.7% | ₹347 Cr |
| Borrowings | ₹63 Cr ▼26.7% | ₹86 Cr ▼45.9% | ₹159 Cr ▲467.9% | ₹28 Cr |
| Other Liabilities | ₹254 Cr ▲7.2% | ₹237 Cr ▲24.1% | ₹191 Cr ▲20.1% | ₹159 Cr |
| Total Liabilities | ₹977 Cr ▲5.1% | ₹930 Cr ▲11.9% | ₹831 Cr ▲39.7% | ₹595 Cr |
| Assets | ||||
| Fixed Assets | ₹394 Cr ▲6.5% | ₹370 Cr ▼3.6% | ₹384 Cr ▲107.6% | ₹185 Cr |
| CWIP | ₹205 Cr ▲10.2% | ₹186 Cr ▲53.7% | ₹121 Cr ▲86.2% | ₹65 Cr |
| Investments | ₹0 Cr ▼100.0% | ₹26 Cr ▲0.0% | ₹26 Cr ▼18.8% | ₹32 Cr |
| Other Assets | ₹378 Cr ▲8.6% | ₹348 Cr ▲15.6% | ₹301 Cr ▼4.1% | ₹314 Cr |
| Total Assets | ₹977 Cr ▲5.1% | ₹930 Cr ▲11.9% | ₹831 Cr ▲39.7% | ₹595 Cr |
Values in ₹ Cr · Source: Screener.in
Cash Flow Statement
| Item | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|
| Operating CF | ₹190 Cr ▲21.0% | ₹157 Cr ▲52.4% | ₹103 Cr |
| Investing CF | ₹-84 Cr ▲68.5% | ₹-267 Cr ▼434.0% | ₹-50 Cr |
| Financing CF | ₹-107 Cr ▼208.1% | ₹99 Cr ▲320.0% | ₹-45 Cr |
| Net Cash Flow | ₹0 Cr ▲100.0% | ₹-11 Cr ▼237.5% | ₹8 Cr |
| Free Cash Flow | ₹99 Cr ▲176.7% | ₹-129 Cr ▼1533.3% | ₹9 Cr |
Values in ₹ Cr · Source: Screener.in
Key Ratios History
| Metric | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|
| Debtor Days | 36d ▲0.0% | 36d ▲0.0% | 36d |
| Inventory Days | 200d ▲26.6% | 158d ▼13.2% | 182d |
| Days Payable | 221d ▲20.1% | 184d ▲12.9% | 163d |
| Cash Conv. Cycle | 14d ▲40.0% | 10d ▼81.8% | 55d |
| Working Capital Days | 9d ▲550.0% | -2d ▼106.7% | 30d |
| ROCE | 32.0% ▲28.0% | 25.0% | — |
Source: Screener.in · Lower days = better efficiency
About CORONA Remedies Limited
Incorporated in August 2004, Corona Remedies Limited is a pharmaceutical company developing, manufacturing, and marketing products in women’s healthcare, cardiology, pain management, urology, and other therapeutic areas.[1]
Healthcare · Pharmaceuticals & Biotechnology
Related Analysis
Frequently Asked Questions
What is CORONA Remedies Limited share price today?▾
CORONA Remedies Limited (CORONA) is currently trading at ₹1,739 on NSE, down 0.22% as of the last market session. Prices update daily after market close on MarketNetra.
Is CORONA Remedies Limited available in F&O (Futures & Options)?▾
Yes, CORONA Remedies Limited (CORONA) is part of the NSE F&O segment with a lot size of 1 shares. Options are available with monthly expiry contracts. You can track the full option chain and OI analysis on MarketNetra.
What is CORONA Remedies Limited 52-week high and low?▾
CORONA Remedies Limited's 52-week high is ₹1,744 and the 52-week low is ₹1,337. The current price of ₹1,739 is 0.3% below the 52W high.
What is CORONA Remedies Limited P/E ratio?▾
CORONA Remedies Limited's current P/E ratio is 66.2. This indicates the market is paying ₹66.2 for every ₹1 of earnings. Compare this to the sector average to assess relative valuation.
How to trade CORONA Remedies Limited options?▾
CORONA Remedies Limited options are traded on NSE with monthly expiry contracts (lot size: 1 shares). To trade CORONA options: select your expiry on the option chain page, identify key OI strikes, check the PCR and buildup type on OI analysis, and review FII/DII flows for institutional sentiment before taking a position.